Seek­ing a place among gi­ants in the on­colyt­ic virus field, lit­tle Cold Genesys bags $22M Se­ries C

7 years ago
Financing

Skin re­gen­er­a­tion com­pa­ny Po­lar­i­tyTE re­veals SEC in­ves­ti­ga­tion, prob­ing in­to its lead prod­uct, for­mer CFO and cur­rent ...

7 years ago
Pharma

Af­fimed lands mile­stone from Roche; Puma touts new PHII da­ta on cer­vi­cal can­cer

7 years ago
News Briefing

Bris­tol-My­ers and Star­board Val­ue spar over $74B Cel­gene buy­out as share­hold­er vote looms

7 years ago
Deals

Roche, Ab­b­Vie forced to slam brakes on myelo­ma stud­ies of star drug Ven­clex­ta af­ter re­searchers flag high­er risk of ...

7 years ago
R&D

Vivek Ra­maswamy’s Urovant claims a big win in PhI­II — but ques­tions linger about a cheap gener­ic and their ...

7 years ago
R&D

Roche stacks up Tecen­triq nods, fol­low­ing up breast can­cer ap­proval with small cell lung can­cer

7 years ago
Pharma

Is a new CEO in the cards at Sanofi as suc­ces­sion plan­ning heats up for top team?

7 years ago
People

Part­ner­ing talks led to Bio­gen’s $800M Night­star buy­out as play­ers clus­tered around the hot deal ta­ble for gene ...

7 years ago
Deals

Aim­mune wins 12-month re­view and ad­com for peanut al­ler­gy drug; Phase­Bio flies on ear­ly da­ta for Bril­in­ta re­ver­sal ...

7 years ago
News Briefing

Amarin posts an­oth­er round of promis­ing car­dio out­comes da­ta for Vas­cepa. Cue more M&A chat­ter and ar­gu­ment

7 years ago
R&D

Al­ler­gy Ther­a­peu­tic­s' im­munother­a­py prospect tar­nished af­ter birch vac­cine flops in PhI­II

7 years ago
R&D

Bio­haven is bet­ting hun­dreds of mil­lions it can hus­tle ahead of ri­vals in a block­buster race. A quick M&A deal could ...

7 years ago
Pharma

Aer­pio shares tum­ble as lead eye drug trips up in mid-stage di­a­bet­ic retinopa­thy study

7 years ago
R&D

On­col­o­gy dom­i­nates a 'Cam­bri­an ex­plo­sion' in Chi­na's drug pipeline as McK­in­sey gu­ru bets on a burst of in­no­va­tion

7 years ago
China

Lit­tle Der­mi­ra’s shares zoom up on promis­ing PhI­Ib atopic der­mati­tis da­ta — but the road ahead is ul­tra risky and ...

7 years ago
R&D

Arch-backed biotech hauls in a fast B round as its re­born an­ti-psy­chot­ic zooms to a PhII fin­ish line

7 years ago
Financing
Startups

Months away from com­plet­ing a key sick­le cell tri­al, up­start Imara scores $63M in round co-led by Ar­ix, Or­bimed

7 years ago
Financing

Gilead CEO Mil­li­gan capped a rocky year — and his ca­reer — with the new #1 com­pen­sa­tion pack­age in the big ...

7 years ago
People

As­traZeneca vet Jen­nifer But­ler takes charge of In­nate Phar­ma's US biz; C4 raids NI­BR

7 years ago
Peer Review

Des­per­ate­ly seek­ing a turn­around, be­lea­guered vet­er­an fund man­ag­er Wood­ford hits out at crit­ics, fake news

7 years ago
People

Gen­fit read­ies its $120M IPO; Karyopharm shares boost­ed af­ter an FDA de­lay for se­linex­or

7 years ago
News Briefing

Scott Got­tlieb to bio­phar­ma: You want­ed us to help mod­ern­ize R&D, now go out and do it

7 years ago
Pharma

Spec­trum yanks mar­ket­ing ap­pli­ca­tion for Neu­las­ta ri­val af­ter FDA de­mands more da­ta

7 years ago
R&D
First page Previous page 966967968969970971972 Next page Last page
A service from the Financial Times